An interventional study of Urotherapy Education in Duchenne Muscular Dystrophy (DMD) and Lower Urinary Tract Symptoms (LUTS), sponsored by Lokman Hekim University. Not yet recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Lokman Hekim University · Not applicable, Interventional, and Other
This study aims to investigate the effects of urotherapy education provided to families of children with Duchenne muscular dystrophy on parents' knowledge, lifestyle changes, and satisfaction with the education. Families will receive an online urotherapy education session covering lower urinary tract function, bladder and bowel habits, appropriate toileting behaviors, lifestyle recommendations, and related management strategies. Parents' knowledge and awareness will be assessed before the education, immediately after the education, and two weeks later. Satisfaction with the education will also be evaluated after the session.
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that may also be accompanied by lower urinary tract symptoms. Urotherapy is a conservative, non-pharmacological approach that includes education on bladder and bowel function, appropriate voiding and defecation habits, lifestyle modifications, and strategies for managing lower urinary tract symptoms.
This prospective interventional study will evaluate the effects of an online urotherapy education program provided to families of children with DMD. The education will be delivered remotely in a single session of approximately three hours. Participants will be assessed before the education, immediately after the education, and two weeks later and 2 months after. The study will examine changes in parents' knowledge and awareness of urotherapy-related behaviors and lifestyle practices, as well as their satisfaction with the education provided.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 108 are open to participants now.
This study's planned enrollment of 50 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Browse Muscular Dystrophy, Duchenne studies →Lokman Hekim University is the lead sponsor of 43 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a single online urotherapy education session lasting approximately three hours. The education will include information on lower urinary tract anatomy and function, bladder and bowel symptoms, appropriate voiding and defecation habits and postures, lifestyle modifications, fluid intake, and strategies for managing lower urinary tract symptoms. Knowledge and awareness will be assessed before the education, immediately after the education, and two weeks later and eight weeks later, and satisfaction with the education will be evaluated after the session.
Behavioral: Urotherapy Education
Participants will receive a single online urotherapy education session lasting approximately three hours. The education will include information about lower urinary tract anatomy and function, lower urinary tract symptoms, bladder and bowel habits, appropriate voiding and defecation postures, scheduled voiding and defecation, fluid intake, lifestyle modifications, pelvic floor muscle awareness, and general strategies for managing lower urinary tract symptoms. Educational materials may include visual materials, videos, and other supporting resources.
Change in Urotherapy Knowledge Level
Parents' knowledge of urotherapy will be assessed using a 10-item knowledge test developed by the researchers based on the educational content. The test consists of five true/false and five multiple-choice questions. Each correct answer is worth 10 points, resulting in a total score ranging from 0 to 100. Higher scores indicate a higher level of knowledge about urotherapy.
Time frame: Baseline, two weeks after, 8 weeks after
Change in Urotherapy-Related Lifestyle Behaviors
Urotherapy-related lifestyle behaviors will be assessed using awareness questions developed by the researchers. The questions evaluate voiding frequency, defecation frequency, daily water intake, consumption of tea, coffee, and carbonated beverages, appropriate toileting posture, and implementation of lifestyle recommendations introduced during the urotherapy education. Changes in these behaviors after the education will be evaluated.
Time frame: After 2 weeks and 8 weeks
Satisfaction With Urotherapy Education
Satisfaction with the urotherapy education will be assessed using an 8-item satisfaction questionnaire developed by the researchers. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 8 to 40, with higher scores indicating greater satisfaction with the education.
Time frame: Baseline
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 1 month is below that.
Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Lokman Hekim University